Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Allegra (fexofenadine) Treatment Report
What is Allegra?

Allegra (Fexofenadine) is an allergy medicine taken for seasonal allergies and hives, to relieve symptoms like itchy eyes, runny nose, and sneezing. Unlike some other allergy medication Allegra does not cause drowsiness and driving is not contraindicated.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Seasonal allergies 11 3
Allergies 8 0
Other 3 1
General health 2 1
Headaches 2 0
Urticaria (hives) 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
1 20%
None
4 80%

Most commonly reported side effects

Jittery feeling
1 20%
  • Mild
  • Moderate
  • Severe

Dosages

  30mg as needed daily mg as needed 60 mg daily 120 mg daily 180 mg daily 360 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 17 Number of Patients: 17 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Allegra (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
1 100% Did not seem to work: 100%

See all 1 patient who’ve stopped taking Allegra

Currently Taking Allegra

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
2
0
1
2
6

Stopped Taking Allegra

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
1
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
4 80%
Usually
0 0%
Sometimes
1 20%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
2 40%
Not at all
3 60%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 20%
< $25
3 60%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.